Medical - Healthcare Information Services
Compare Stocks
2 / 10Stock Comparison
AMWL vs DOCS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
AMWL vs DOCS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Information Services |
| Market Cap | $119M | $5.17B |
| Revenue (TTM) | $182M | $638M |
| Net Income (TTM) | $-88M | $239M |
| Gross Margin | 38.7% | 89.7% |
| Operating Margin | -50.6% | 37.4% |
| Forward P/E | — | 16.6x |
| Total Debt | $5M | $12M |
| Cash & Equiv. | $182M | $210M |
AMWL vs DOCS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| American Well Corpo… (AMWL) | 100 | 2.8 | -97.2% |
| Doximity, Inc. (DOCS) | 100 | 44.1 | -55.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMWL vs DOCS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMWL is the clearest fit if your priority is momentum.
- +5.3% vs DOCS's -55.0%
DOCS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.03
- Rev growth 20.0%, EPS growth 54.2%, 3Y rev CAGR 18.4%
- -51.5% 10Y total return vs AMWL's -98.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs AMWL's -2.0% | |
| Quality / Margins | 37.5% margin vs AMWL's -48.2% | |
| Stability / Safety | Beta 1.03 vs AMWL's 1.47, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +5.3% vs DOCS's -55.0% | |
| Efficiency (ROA) | 20.7% ROA vs AMWL's -25.1%, ROIC 20.0% vs -95.1% |
AMWL vs DOCS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AMWL vs DOCS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
DOCS is the larger business by revenue, generating $638M annually — 3.5x AMWL's $182M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, DOCS holds the edge at +9.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $182M | $638M |
| EBITDAEarnings before interest/tax | -$59M | $250M |
| Net IncomeAfter-tax profit | -$88M | $239M |
| Free Cash FlowCash after capex | -$42M | $314M |
| Gross MarginGross profit ÷ Revenue | +38.7% | +89.7% |
| Operating MarginEBIT ÷ Revenue | -50.6% | +37.4% |
| Net MarginNet income ÷ Revenue | -48.2% | +37.5% |
| FCF MarginFCF ÷ Revenue | -22.9% | +49.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +9.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +44.5% | -16.2% |
Valuation Metrics
AMWL leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $119M | $5.2B |
| Enterprise ValueMkt cap + debt − cash | -$59M | $5.0B |
| Trailing P/EPrice ÷ TTM EPS | -1.20x | 23.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 16.61x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.29x |
| EV / EBITDAEnterprise value multiple | — | 20.85x |
| Price / SalesMarket cap ÷ Revenue | 0.48x | 9.06x |
| Price / BookPrice ÷ Book value/share | 0.46x | 4.77x |
| Price / FCFMarket cap ÷ FCF | — | 19.38x |
Profitability & Efficiency
DOCS leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-33 for AMWL. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMWL's 0.02x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs AMWL's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -33.5% | +24.4% |
| ROA (TTM)Return on assets | -25.1% | +20.7% |
| ROICReturn on invested capital | -95.1% | +20.0% |
| ROCEReturn on capital employed | -36.6% | +22.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 9 |
| Debt / EquityFinancial leverage | 0.02x | 0.01x |
| Net DebtTotal debt minus cash | -$178M | -$197M |
| Cash & Equiv.Liquid assets | $182M | $210M |
| Total DebtShort + long-term debt | $5M | $12M |
| Interest CoverageEBIT ÷ Interest expense | -239.18x | — |
Total Returns (Dividends Reinvested)
DOCS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DOCS five years ago would be worth $4,847 today (with dividends reinvested), compared to $262 for AMWL. Over the past 12 months, AMWL leads with a +5.3% total return vs DOCS's -55.0%. The 3-year compound annual growth rate (CAGR) favors DOCS at -9.2% vs AMWL's -43.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +47.4% | -40.7% |
| 1-Year ReturnPast 12 months | +5.3% | -55.0% |
| 3-Year ReturnCumulative with dividends | -82.2% | -25.2% |
| 5-Year ReturnCumulative with dividends | -97.4% | -51.5% |
| 10-Year ReturnCumulative with dividends | -98.5% | -51.5% |
| CAGR (3Y)Annualised 3-year return | -43.8% | -9.2% |
Risk & Volatility
Evenly matched — AMWL and DOCS each lead in 1 of 2 comparable metrics.
Risk & Volatility
DOCS is the less volatile stock with a 1.03 beta — it tends to amplify market swings less than AMWL's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 78.1% from its 52-week high vs DOCS's 33.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.47x | 1.03x |
| 52-Week HighHighest price in past year | $9.15 | $76.51 |
| 52-Week LowLowest price in past year | $3.71 | $20.55 |
| % of 52W HighCurrent price vs 52-week peak | +78.1% | +33.6% |
| RSI (14)Momentum oscillator 0–100 | 58.1 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 58K | 2.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $42.79 |
| # AnalystsCovering analysts | — | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | +2.3% |
DOCS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMWL leads in 1 (Valuation Metrics). 1 tied.
AMWL vs DOCS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AMWL or DOCS a better buy right now?
For growth investors, Doximity, Inc.
(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). Doximity, Inc. (DOCS) offers the better valuation at 23. 1x trailing P/E (16. 6x forward), making it the more compelling value choice. Analysts rate Doximity, Inc. (DOCS) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AMWL or DOCS?
Over the past 5 years, Doximity, Inc.
(DOCS) delivered a total return of -51. 5%, compared to -97. 4% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: DOCS returned -51. 5% versus AMWL's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AMWL or DOCS?
By beta (market sensitivity over 5 years), Doximity, Inc.
(DOCS) is the lower-risk stock at 1. 03β versus American Well Corporation's 1. 47β — meaning AMWL is approximately 43% more volatile than DOCS relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 2% for American Well Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — AMWL or DOCS?
By revenue growth (latest reported year), Doximity, Inc.
(DOCS) is pulling ahead at 20. 0% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: American Well Corporation grew EPS 57. 1% year-over-year, compared to 54. 2% for Doximity, Inc.. Over a 3-year CAGR, DOCS leads at 18. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AMWL or DOCS?
Doximity, Inc.
(DOCS) is the more profitable company, earning 39. 1% net margin versus -38. 4% for American Well Corporation — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AMWL or DOCS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AMWL or DOCS better for a retirement portfolio?
For long-horizon retirement investors, Doximity, Inc.
(DOCS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03)). Both have compounded well over 10 years (DOCS: -51. 5%, AMWL: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AMWL and DOCS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMWL is a small-cap quality compounder stock; DOCS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.